Product Description
Aviscumine, a recombinant lectin I, has been identified as an immunomodulatory agent within a new class of ribotoxic stress-inducing anticancer substances that have demonstrated efficacy in phase I/II trials. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666656/)
Mechanisms of Action: 28S Ribosomal Subunit Deactivator
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cytavis Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colorectal Cancer|Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CY503C2 | P2 |
Terminated |
Colorectal Cancer |
2012-08-01 |
|
CY-503 Phase II Malignant Melanoma | P2 |
Completed |
Melanoma |
2011-12-31 |
|
2008-005536-32 | P2 |
Terminated |
Colorectal Cancer |
2011-06-28 |
|
CY503C1 | P2 |
Completed |
Melanoma |
2009-08-01 |